September 18, 2025
6 min watch
In this video, Joshua Brody, MD, discusses primary analysis results from LOTIS-7 and SUNMO trials, both of which are investigating combination therapies for diffuse large B-cell lymphoma.
“These two trials were practically a bit different,” Brody, director of the lymphoma immunotherapy program at The Tisch Cancer Institute at Mount Sinai, said. “But [they are] conceptually very similar, because they are both combining a CD20 x CD3 bispecific with an antibody-drug conjugate.”
The phase 1b LOTIS-7 trial is evaluating the combination of lucatumumab tesirine-lpyl (Zynlonta, ADC Therapeutics) plus glofitamab-gxbm (Columbic, Genentech) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who had received at least one systematic therapy.
Among 22 efficacy-evaluable patients, the complete remission rate was “extraordinarily high” at 90.9%, Brody said, noting the rate of cytokine release syndrome may have been lower with this drug combination compared with glofitamab alone.
In the phase 3 SUNMO trial, 208 patients with relapsed or refractory DLBCL were randomly assigned 2:1 to mosunetuzumab (Lunsumio, Genentech) plus polatuzumab vedotin (Polivy, Genentech), also known as M-Pola, or standard-of-care rituximab plus gemcitabine and oxaliplatin (R-GemOx).
The overall response rate was 70.3% in the M-Pola group compared with 40% in the R-GemOx group, and M-Pola was well tolerated overall, Brody said.
“This could lead to a label, an FDA approval, for M-Pola for relapsed/refractory DLBCL in the near future,” he added.
Results were presented at Society of Hematologic Oncology’s Annual Meeting.
References:
- Alderuccio JP, et al. Abstract ABCL-777. Presented at: SOHO Annual Meeting; Sept. 3-6, 2025; Houston.
- Westin J, et al. Abstract ABCL-1492. Presented at: SOHO Annual Meeting; Sept. 3-6, 2025; Houston.
Sources/Disclosures
Collapse
Healio Interviews
Disclosures:
ADC Therapeutics and Sobi funded the LOTIS-7 trial, and F. Hoffmann-La Roche sponsored the SUNMO trial. The Brody Lab receives funding from ADC Therapeutics, AstraZeneca, Genentech/Roche, Merck and Pfizer.
